MONROVIA, May 7 (LINA) - An official of the clinical trial known as the Partnership for Research on Ebola Vaccine in Liberia (PREVAIL) has disclosed that 1,500 volunteers have successfully participated in Phase Two of the Ebola vaccine study in Liberia.
Co-Principal Investigator of PREVAIL, Dr. Stephen Kennedy, said the vaccine study was conducted by the Liberia-US Clinical Research Partnership which was formed in October 2014 as part of the response to the Ebola outbreak in Liberia, Guinea and Sierra Leone.
Dr. Kennedy made the disclosure Wednesday evening at a press conference held at the PREVAIL office in the Monrovia suburb of Sinkor with three days left for Liberia to be declared an Ebola-free country.
He indicated that the last participant was vaccinated at the Redemption Hospital, one of the study sites, on April 30. This milestone was reached less than three months after the first participant was enrolled on February 2, 2015.
He pointed out that all participants of the Ebola vaccine study will continue to be monitored by the study team at the Redemption Hospital for 12 months from the date of their enrollment.
“We are extremely pleased to have completed enrollment in the first Ebola vaccine study that was conducted in Liberia and to participants who will have a global impact; most importantly, we thank all of the study participants who have become our partners in this groundbreaking clinical research effort,” Dr Kennedy said.
LINA CB/TSS/PTK